Physician profile
Timothy Poquette
NPI 1427613447
$4,160.89
in general payments reported to CMS, 2019-2025
18 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $888 · 2023: $782 · 2024: $803 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,956.11 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $339.19 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $243.29 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $229.81 | 2022-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.34 | 2022-2025 | Caplyta |
| Owp Pharmaceuticals, INC. | $179.16 | 2021-2025 | Subvenite, Lamotrigine |
| Sunovion Pharmaceuticals INC. | $175.40 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $169.80 | 2024-2025 | Spravato, Invega Sustenna |
| Braeburn INC. | $148.45 | 2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $145.02 | 2021-2025 | Trintellix |
| Lundbeck LLC | $143.91 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $76.43 | 2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $54.99 | 2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $33.93 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $24.06 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $22.06 | 2025 | Sublocade |
| Tris Pharma INC | $18.71 | 2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $16.23 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Poquette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.